A First-in-human, Single-center, Placebo-controlled, Randomized, Double-blind Study in Healthy Subjects to Evaluate Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam After Oral Single and Multiple Ascending Dosing of KAND145
Latest Information Update: 10 May 2024
At a glance
- Drugs KAND 145 (Primary)
- Indications Chronic lymphocytic leukaemia; Inflammation; Ovarian cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Kancera
- 03 May 2024 According to a Kancera media release, analysis of potential effects of interaction with other drugs and the statistical analysis are ongoing. These results will be reported in connection with the next financial interim report.
- 03 May 2024 Results published in the Kancera Media Release.
- 19 Apr 2024 Status changed from recruiting to completed.